CompletedNot Applicable

Benefit of DAA Therapy in HCV Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia

France47 participantsStarted 2017-03-01

Plain-language summary

Mixed cryoglobulinemia (MC) is common in patients with chronic hepatitis C virus (HCV) infection. Direct-acting antiviral (DAA) regimens are today very effective with sustained virological response rates (SVR12) above 90%. The objective of this study was to investigate the impact of DAA therapy on cryoglobulin clearance in patients with HCV-associated MC.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * hepatitis C virus (HCV) infected patients * symptomatic or asymptomatic mixed cryoglobulinemia * coinfected or not with HIV * treated by direct-acting antiviral (DAA) treatment * at least one cryoglobulin measurement before and after DAA Exclusion Criteria: \-

What they're measuring

Cryoglobulin level at the end of therapy

Timeframe: End of treatment (12 or 24 weeks)

Trial details

NCT IDNCT03342261

SponsorHospices Civils de Lyon

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2017-11-01

View on ClinicalTrials.gov More Hepatitis C, Chronic trials